semaglutide for maintenance therapy on or tirzepatide GLP-1 Maintenance Program | Semaglutide

External resources SUSTAIN-6 Trial - New England Journal of Medicine : The landmark cardiovascular outcomes trial showing 26% MACE reduction with semaglutide in high-risk type 2 diabetes patients, providing foundational evidence for semaglutide cardiovascular benefit

Whats more, stopping semaglutide too soon may lead to rebound weight gain or high blood sugar

Lamminoacido Carnitina apporta notevoli benefici allorganismo, sia nei regimi alimentari ipocalorici e sia a livello di forza e resistenza utilizzando per lappunto i grassi per aumentare il livello energetico

Management strategies should address modifiable risk factors while continuing semaglutide if it is providing metabolic benefits

& Gorgoulis, V